study of the early diagnosis of relapsing breast carcinoma€¦ · ganotherapy adrenal cortex...

62 REGUMED Institut für Regulative Medizin, 82166 Gräfelfing • RTI Volume 26 • May 2002

Study of the early diagnosis of relapsing breast carcinoma

Dr. med. Santos Martín, Granollers, Spain

INTRODUCTION

It is becoming increasingly impossible to argue

away the fact that there is a connection between

electroacupuncture points and the existence of

certain pathologies. Studies even exist which not

only connect values at certain points with disease

but also with life expectancy. The medical profes-

sion’s aphorism that “there are no diseases, only

sick people” is well-known. Just as a disease can

be defined by certain signs and symptoms, the

same can be expected when measuring the elec-

troacupuncture points of chronically ill patients,

especially cancer patients.

STUDY

The study I am going to present provides an an-

swer, substantiated by statistical analysis, to a

number of questions. It concerns a study of around

170 patients suffering from in various stages of

breast carcinoma. The information it yields on acu-

puncture points cannot be applied to other tu-

mours. However, it can be assumed that similar

characteristics can be found at other points if the

same or similar techniques are used.

The study provides answers to the following

questions:

1. Are there one or more points which indicate

breast carcinoma, irrespective of whether a lo-

cal or metastasising carcinoma?

2. After determining the said points: how do they

behave if the disease progresses/enters a sta-

tionary phase?

3. What is the extent of the ability of these points

as regards sensitivity and specificity?

4. Are these points able to predict developments?

Criteria

We employed well-known BRT assessment crite-

ria. Points were considered pathological if their

behaviour – at between 76 and 86 conductivity –

was as follows:

1. The value measured for the point was less than

40

2. The indicator reading for the point dropped by

more than 20 units of measurement.

Method

To determine precisely those points which are re-

presentative of breast carcinoma, several measure-

ments were taken on patients with this disease.

We began with the most seriously affected women,

namely those in the advanced stage (III and IV).

We observed the following:

1. Women in the advanced stage (III and IV) dis-

played five clearly disturbed points: organ de-

generation [OD] 1d, 2 and 5 as well as triple

warmer [TW] 1d and 2. Even after just one

measurement, it was evident that these points

were pathological. This deterioration in the

points was almost always observed in the hand

on the same side of the body as the breast car-

cinoma, with changes occasionally occurring on

both sides of the body. This might possibly in-

dicate a link with increased aggression on the

part of the tumour and also with unfavourable

prognosis factors. The number of points dis-

playing a pathological value is in inverse pro-

portion to the body’s powers of resistance. This

means the more points affected, the lower the

body’s powers of resistance or, to put it another

way, the lower the body’s powers of resistance,

Colloquium staged by the International Medical Working Group BICOM Resonance Therapy and BICOM Resonanz-

Therapie-Gesellschaft from 3 to 5 May 2002 in Fulda

www.bioresonance.com

REGUMED Institut für Regulative Medizin, 82166 Gräfelfing • RTI Volume 26 • May 2002 63

the more points will be affected. The prognosis

is particularly gloomy for patients where, in

addition to the five points previously measured,

the hypothalamus points (TW-20) displayed

pathological values. This means that the values

for the hypothalamus points (TW-20) had dete-

riorated in patients in stage IV, these women

having undergone chemotherapy at the same

time. Patients in stage III displayed virtually

normal values at the hypothalamus points (TW-

20), irrespective of whether they had undergone

chemotherapy or not.

2. There was normally no significant change in

the above-mentioned points in women with car-

cinomas in stages I and II. Not even following

basic therapy according to the traditional plan.

For this reason we were compelled to look for a

therapy type which would enable us to reveal

these points. This is how we came upon provo-

cation therapy. This is a new type of therapy

for us which I should now like to explain in

more detail:

To identify the true weak points of the body

accurately, we do not need basic therapy which

compensates the patient, but provocation ther-

apy which places the body in a kind of “state of

emergency”. For this we place the input elec-

trode on the patient’s hand on the side of the

body with the carcinoma. The output is

placed on the modulation mat laid along the

back. The program parameters are: A, all fre-

quencies, amplification 45, therapy time 3 min-

utes. Another measurement is then carried out.

3. Following provocation therapy, the five points

(organ degeneration [OD] 1d, 2 and 5 and triple

warmer [TW] 1d and 2) revealed a marked de-

terioration in patients with an active tumour.

There is a clear relationship between the devel-

opment of the tumour marker and the lack of

reaction at the electroacupuncture points.

4. The “deterioration” in values at electroacu-

puncture points was measured long before

changes in the tumour marker became visible or

a change became apparent in any other symp-

toms or signs. This illustrates the huge impor-

tance of measuring these points since it enables

us to respond during the phase when the disease

has not yet “realised its potential”.

CONCLUSION

Bioresonance therapy offers new opportunities for

the future of oncology. Based on the above-men-

tioned results, it enables us:

1. to identify, at an early stage, the advance of

breast carcinoma.

2. to influence the advance of the disease or its re-

tardation using specific programs, the patient’s

own information or other means before the dis-

ease breaks out again.

3. to evaluate oncological therapies, both conven-

tional such as chemotherapy and hormone ther-

apy and unconventional.

This, in turn, allows us:

1. to adapt medication dosages.

2. to avoid unnecessary expense.

3. to limit the toxicity of drugs on the basis of

their inefficacy and thereby avoid side effects

and accompanying symptoms which, for their

part, reduce not only the body’s immune re-

sponse and homeostatic reaction but also that

precious element, quality of life.

I hope that there are other therapists who can reaf-

firm this information and are prepared to develop

working models for other types of tumours.



Diagnosis and BICOM therapy of rheumatic disorders –

case histories, dealing with initial exacerbation

Dr. med. Christa Lund, Bad Schwartau

Diagnosing rheumatic disorders

1. Clinical: symptoms, location, time

2. Multi-factorial causes

3. Resonance diagnosis

Toxins: Aflatoxin

Bacterial fragment

Botulinum

Parasitic toxins (trichinosis nosodes!)

Other fungal toxins

Bacteria: Clostridium

Staphylococci

Yersinia

Borrelia

Interference fields: Dental - maxillomandibular area (also malocclusion)

Tonsils (scar interference field)

Intestine

Focal stress!

Acid-base balance!

Colloquium staged by the International Medical Working Group BICOM Resonance Therapy and BICOM Resonanz-

Therapie-Gesellschaft from 3 to 5 May 2002 in Fulda



Treating rheumatic disorders

A) Non-specific: 1. Nutrition

2. Balancing the energetic state (vegetative reactivity)

3. Detoxifying measures

4. Treating acidaemia

5. Enzyme therapy

6. Homeopathic treatment

7. Phytotherapy

8. Isopathy

9. Symbiosis control

10. Interference field and focal therapy

11. Orthomolecular

12. Autologous blood

B) Treatment in the light of regulation blocks:

1. Toxin elimination

2. Parasites

3. Interference fields

4. Nosodes (bacteria, chlamydia)

C) Follow-up treatment: Physical

Neurotherapeutic

Organotherapeutic



“Initial exacerbation”

1. Educating the patient

2. Chronic disease – acute condition -

activation of endogenous counter-measures

= regulation therapy

3. Observing biorhythms

(lung, liver, kidneys)

4. Symptoms depending on patient’s vegetative reactivity

5. Options for therapy

Prevention: avoiding substances which will intensify the reaction

Synchronous: Elimination with resonance therapy,

e. g. Engystol, Okoubaka

via kidneys Solidago,

via liver Chelidonium, milk thistle

6. Beware! Exacerbation induced by interference fields!



Suggested BICOM therapy

Toxin elimination

Elimination via liver or kidneys Program no. 970 (H+Di)

I: quadr. flex. electrode on thymus area

O: magnetic articulated electrode on liver area

O: 1 foot on foot electrode

Then Ai program O: both hands via hand electrodes.

Therapy type: Ai

Frequency: sweep in 3 seconds

Amplification: Ai=64, no stages

Continuous operation

Therapy time: 3 minutes

Parasite therapy according to individual setting,

at least 3 therapy sessions

O: magnetic articulated electrode on solar plexus

O: 1 hand on hand electrode

Interference field therapy via elimination of scar interference, program, no. 910 (Ai)

I: opposite hand or foot electrode to scar

O: magnetic articulated electrode on scar area

Pain therapy Rheumatic pain, program no. 631 (H+Di)

I: magnetic articulated electrode on better joint

O: magnetic articulated electrode on more painful joint and

also magnetic depth probe on scar

Hip joint Hip joint problems (restricted movement),

program no. 620 (Di)

I: roller electrode on affected hip

O: magnetic articulated electrode on coccyx

Inflammations Tissue process, chronic-degenerative,

program no. 923 (H+Di)

I: 5 spirals on fingers of right hand

O: magnetic articulated electrode between left shoulder

joint/clavicle

Lymph activation Lymph activation, program no. 930 (A)

I: 4 right-spin spirals in groins and armpits

O: large flexible electrode on abdomen



Nosode therapy A or Ai.

Or A and Ai.

O: 1 hand on hand electrode

O: magnetic articulated electrode on solar plexus

Setting A (provocation): Frequency: sweep in 3 seconds

Amplification: A = 0.50, no stages



Setting Ai (gentle inverse treatment) Frequency: sweep in 3 seconds

Amplification: A = 1.00, no stages





CASE STUDIES

RHEUMATIC DISORDERS

Case 1: PCP

47-year-old female (V. H.). Painful swellings in

the large joints for past 12 months. Persistent

oedematous swelling in the fingers following ex-

traction of all (!) teeth.

Findings from resonance diagnosis:

Chlamydia D15, D30, D60

Entamoeba histolytica

Clostridium difficile D10

Staphylococcus aureus

Mucor mucedo

toxic stress: Botulinum D30, prednisolone D60,

dioxin D100

acidaemia

organ stress:

tonsils, liver, pancreas, dental-maxillomandib-

ular area (with teeth absent)

maxillomandibular: radicular cysts: radiological

metal residue with cysts in upper jaw.

Therapy in order of application:

1. parasite

2. toxin elimination

3. nosode therapy for microbial infestation.

Accompanying medication:

enzyme therapy

lymphatic agents

antacids

isopathy.

Treatment period: 2 months.

Case 2: PCP

45-year-old female (B. W.). Painful swellings in

the joints of all the limbs for past 3 years. Diffuse

back pain. Cortisone and analgesics continuously

for a year.


Fasciola hepatica

Chlamydia

Mucor racemosus

Yersinia enterocolitica

Shigella

Staphylococcus aureus


1. parasite

2. Chlamydia

3. other microbial pathogens.

Following initial improvement, deterioration after 7

teeth extracted in one session. Further staphylo-

coccus treatment.

Accompanying therapy:

symbiosis control, enzyme therapy, vit. E, or-

ganotherapy adrenal cortex

non-specific treatment of consequences of joint

deformities (e. g. pain following exercise, ar-

throsis).

Case 3: shoulder-hand syndrome

65-year-old male (D. O.). Pain in the back of the

neck and right upper arm for 2 years, frequent

headaches. Rupture of head of the biceps on af-

fected side.

Interference fields:

cholecystectomy scar and

dental extraction scar on the right side.


Chlamydia D30

Entamoeba D30

Clostridium difficile D60, D100

Botulinum D60

no other toxic stress as already treated several

years previously.

Therapy:

nosode therapy with accompanying symbiosis

control.

alternating interference field therapy after tes-

ting relevant priority.

Case 4: generalised fibromyalgia

34-year-old male metal worker. Increasing muscu-

lar pain associated with movement for past 2 years.

Scarcely able to climb stairs.


Chlamydia D15, D30

hepatitis B D60

Taenia pisiformis

acidaemia

toxins: lead, cadmium, chromium, cobalt,

nickel, tin




parasite treatment and therapy for microbial

pathogens and also toxin elimination via the

kidneys, in this case running parallel.

began with just one toxin elimination.

at next treatment session, started eliminating

another metal.

careful attention to patient’s stress tolerance!

Due to very risky Chlamydia infection, nosode

therapy for this pathogen was started before com-

pleting toxin elimination.

After 5 weeks’ treatment once or twice a week.

Patient’s verdict: “several hundred % better”.

Relapse 3 months later.


liver fluke (Fasciola hepatica)

enteromycosis

Serratia

Chlamydia D15, D30

heavy metals only identifiable in nosodes.

Interference field:

tonsillectomy scar (did not show initially).

Therapy:

parasite

interference field treatment

nosode therapy for Chlamydia infection and

heavy metals

fungi and Serratia with BICOM Ai therapy (plus

resonance drops)

The patient was virtually symptom-free after 10

days as the initial therapy had improved his auto-

regulatory capacity.

Case 5: diffuse muscular and joint pain

70-year-old male. Borrelia infections diagnosed 1

and 2 years previously. Prior treatment with

antibiotics, cortisone.


Borrelia D30

Chlamydia D60

Mucor racemosus

toxic stress: chlortalonil (pesticide)

organ stress: liver (cirrhosis D30), lungs, ton-

sils.


chlortalonil elimination

Mucor racemosus: Ai therapy and resonance

drops

nosode therapy: Chlamydia and Borrelia

finally non-specific therapy on knee joint to

improve functioning.

Sustained freedom from symptoms.

Case 6: chronic dorsalgia, Bechterew’s disease

26-year-old male. Tendency to infection as a child.

Spastic abdomen 10 years previously. Necessary

symbiosis control was refused. Tonsillectomy 3

years previously, followed by onset of severe back

pain. Only able to sleep sitting up. Movement gen-

erally restricted.


Chlamydia D15-D60

Bang’s disease D60

Salmonella D and TP D60, D100

Streptococcus haemolyticus D60

Klebsiella oxytocin.

fungal infection with Candida tropica, Penicill.

commune

Taenia pisiformis

Interference fields:

tonsillectomy scar

later parasite.


interference field treatment according to tested

priority before further therapy on same day

(provided still tests as interference field)

nosode therapy

Klebsiella: Ai therapy and resonance drops

fungi: Ai therapy and resonance drops

Parasites

Treatment period: 2 months.

Subsequent treatment: symbiosis control.


study of the early diagnosis of relapsing breast carcinoma€¦ · ganotherapy adrenal cortex...

Documents